FI4590324T3 - Ngf spastisuuden hoitoon - Google Patents

Ngf spastisuuden hoitoon

Info

Publication number
FI4590324T3
FI4590324T3 FIEP23777211.6T FI23777211T FI4590324T3 FI 4590324 T3 FI4590324 T3 FI 4590324T3 FI 23777211 T FI23777211 T FI 23777211T FI 4590324 T3 FI4590324 T3 FI 4590324T3
Authority
FI
Finland
Prior art keywords
ngf
mutein
seq
use according
spasticity
Prior art date
Application number
FIEP23777211.6T
Other languages
English (en)
Finnish (fi)
Inventor
Marcello Allegretti
Andrea Aramini
Laura Brandolini
Franca Cattani
Flavio Mantelli
Original Assignee
Dompe Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farm Spa filed Critical Dompe Farm Spa
Application granted granted Critical
Publication of FI4590324T3 publication Critical patent/FI4590324T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
FIEP23777211.6T 2022-09-23 2023-09-25 Ngf spastisuuden hoitoon FI4590324T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22197562.6A EP4342485A1 (en) 2022-09-23 2022-09-23 Ngf for the treatment of spasticity
PCT/EP2023/076387 WO2024062135A1 (en) 2022-09-23 2023-09-25 Ngf for the treatment of spasticity

Publications (1)

Publication Number Publication Date
FI4590324T3 true FI4590324T3 (fi) 2026-07-29

Family

ID=83438536

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP23777211.6T FI4590324T3 (fi) 2022-09-23 2023-09-25 Ngf spastisuuden hoitoon

Country Status (10)

Country Link
EP (3) EP4342485A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025532676A (cg-RX-API-DMAC10.html)
CN (1) CN120239610A (cg-RX-API-DMAC10.html)
AU (1) AU2023345675A1 (cg-RX-API-DMAC10.html)
CA (1) CA3266315A1 (cg-RX-API-DMAC10.html)
DK (1) DK4590324T3 (cg-RX-API-DMAC10.html)
FI (1) FI4590324T3 (cg-RX-API-DMAC10.html)
IL (1) IL319010A (cg-RX-API-DMAC10.html)
PT (1) PT4590324T (cg-RX-API-DMAC10.html)
WO (1) WO2024062135A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4623927A1 (en) 2024-03-27 2025-10-01 Dompe' Farmaceutici SpA Ngf for use in the prevention or treatment of motor impairment caused by neonatal hypoxic-ischemic encephalopathy
WO2026022244A1 (en) 2024-07-23 2026-01-29 Chiesi Farmaceutici S.P.A. A polypeptide for use in the therapeutic management of acute ischaemic stroke
US20260166124A1 (en) * 2024-12-17 2026-06-18 Dompe` farmaceutici S.P.A. Intranasal administration of ngf for the prevention or treatment of retinopathies and optic nerve disorders
EP4763217A1 (en) * 2024-12-17 2026-06-24 Dompé farmaceutici SpA Intranasal administration of ngf for the prevention or treatment of retinopathies and optic nerve disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE257514T1 (de) 1998-10-09 2004-01-15 Scil Proteins Gmbh Verfahren zur gewinnung von aktivem beta-ngf
CN1112215C (zh) * 1999-12-28 2003-06-25 潘晓东 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途
ES2545701T3 (es) 2011-12-19 2015-09-15 Wacker Chemie Ag Nuevos mutantes de proNGF y usos de los mismos en la producción de beta-NGF
CN109071678B (zh) * 2016-03-18 2022-05-20 舒泰神（北京）生物制药股份有限公司 神经生长因子融合蛋白、制备方法及其用途
IT201600112420A1 (it) * 2016-11-08 2018-05-08 Univ Cattolica Del Sacro Cuore Nuova formulazione per via intranasale
WO2019207106A1 (en) 2018-04-27 2019-10-31 Chiesi Farmaceutici Spa Production of nerve growth factor (ngf) and of muteins thereof
AU2020347812B2 (en) * 2019-09-17 2026-05-28 Chiesi Farmaceutici S.P.A. Agent for use in treatment or prevention of ophthalmic disorders
WO2022105847A1 (en) * 2020-11-19 2022-05-27 Staidson (Beijing) Biopharmaceuticals Co. , Ltd. Long-acting nerve growth factor polypeptides and uses thereof

Also Published As

Publication number Publication date
EP4772196A3 (en) 2026-08-19
DK4590324T3 (en) 2026-07-20
CA3266315A1 (en) 2024-03-28
JP2025532676A (ja) 2025-10-01
EP4342485A1 (en) 2024-03-27
EP4590324B1 (en) 2026-06-24
EP4590324A1 (en) 2025-07-30
WO2024062135A1 (en) 2024-03-28
IL319010A (en) 2025-04-01
PT4590324T (pt) 2026-07-20
CN120239610A (zh) 2025-07-01
EP4772196A2 (en) 2026-07-08
AU2023345675A1 (en) 2025-03-06